Replies to post #1599 on Biotech Values

[DewDiligence]

>> raised genr's FY04 R&D expense to $16.2 mil from $11.3 mil and FY EPS to a loss of .26 from .16, thus explaining today's action? <<

canapeas: The higher expenses are for R&D, and I find it hard to see how increasing R&D for the lead program in AMD could be construed as negative. Regards, Dew